近日消息，远大医药旗下产品酒石酸伐尼克兰鼻喷雾剂(OC-01)在国内上市，其特点在于通过鼻喷给药，直接“唤醒”泪腺，从“被动补水”迈向“主动生水”促进泪液分泌，使干眼症治疗进入“原生泪液”时代。干眼症是临床常见的慢性眼表疾病，随着智能手机、电脑深度融入生活，以及人口老龄化加剧，干眼症发病率持续攀升，患者群体庞大。数据显示，国内干眼症发病率介于21%-30%，对应患者约3.6亿人，每4个中国人中就有...
Source Link近日消息，远大医药旗下产品酒石酸伐尼克兰鼻喷雾剂(OC-01)在国内上市，其特点在于通过鼻喷给药，直接“唤醒”泪腺，从“被动补水”迈向“主动生水”促进泪液分泌，使干眼症治疗进入“原生泪液”时代。干眼症是临床常见的慢性眼表疾病，随着智能手机、电脑深度融入生活，以及人口老龄化加剧，干眼症发病率持续攀升，患者群体庞大。数据显示，国内干眼症发病率介于21%-30%，对应患者约3.6亿人，每4个中国人中就有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.